Your browser doesn't support javascript.
loading
Reconstruction of a large-scale outbreak of SARS-CoV-2 infection in Iceland informs vaccination strategies.
Hjorleifsson, Kristjan E; Rognvaldsson, Solvi; Jonsson, Hakon; Agustsdottir, Arna B; Andresdottir, Margret; Birgisdottir, Kolbrun; Eiriksson, Ogmundur; Eythorsson, Elias S; Fridriksdottir, Run; Georgsson, Gudmundur; Gudmundsson, Kjartan R; Gylfason, Arnaldur; Haraldsdottir, Gudbjorg; Jensson, Brynjar O; Jonasdotti, Adalbjorg; Jonasdottir, Aslaug; Josefsdottir, Kamilla S; Kristinsdottir, Nina; Kristjansdottir, Borghildur; Kristjansson, Thordur; Magnusdottir, Droplaug N; Palsson, Runolfur; le Roux, Louise; Sigurbergsdottir, Gudrun M; Sigurdsson, Asgeir; Sigurdsson, Martin I; Sveinbjornsson, Gardar; Thorarensen, Emil Aron; Thorbjornsson, Bjarni; Thordardottir, Marianna; Helgason, Agnar; Holm, Hilma; Jonsdottir, Ingileif; Jonsson, Frosti; Magnusson, Olafur T; Masson, Gisli; Norddahl, Gudmundur L; Saemundsdottir, Jona; Sulem, Patrick; Thorsteinsdottir, Unnur; Gudbjartsson, Daniel F; Melsted, Pall; Stefansson, Kari.
Afiliação
  • Hjorleifsson KE; deCODE Genetics/Amgen Inc., Reykjavik, Iceland; Department of Computing and Mathematical Sciences, California Institute of Technology, Pasadena, CA, USA.
  • Rognvaldsson S; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Jonsson H; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Agustsdottir AB; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Andresdottir M; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Birgisdottir K; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Eiriksson O; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Eythorsson ES; Internal Medicine Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Fridriksdottir R; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Georgsson G; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Gudmundsson KR; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Gylfason A; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Haraldsdottir G; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Jensson BO; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Jonasdotti A; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Jonasdottir A; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Josefsdottir KS; Directorate of Health, Reykjavik, Iceland.
  • Kristinsdottir N; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Kristjansdottir B; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Kristjansson T; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Magnusdottir DN; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Palsson R; Internal Medicine Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
  • le Roux L; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Sigurbergsdottir GM; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Sigurdsson A; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Sigurdsson MI; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland; Operative Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Sveinbjornsson G; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Thorarensen EA; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Thorbjornsson B; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Thordardottir M; Directorate of Health, Reykjavik, Iceland.
  • Helgason A; deCODE Genetics/Amgen Inc., Reykjavik, Iceland; Department of Anthropology, University of Iceland, Reykjavik, Iceland.
  • Holm H; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Jonsdottir I; deCODE Genetics/Amgen Inc., Reykjavik, Iceland; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
  • Jonsson F; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Magnusson OT; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Masson G; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Norddahl GL; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Saemundsdottir J; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Sulem P; deCODE Genetics/Amgen Inc., Reykjavik, Iceland.
  • Thorsteinsdottir U; deCODE Genetics/Amgen Inc., Reykjavik, Iceland; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
  • Gudbjartsson DF; deCODE Genetics/Amgen Inc., Reykjavik, Iceland; School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland.
  • Melsted P; deCODE Genetics/Amgen Inc., Reykjavik, Iceland; School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland. Electronic address: Pall.Melsted@decode.is.
  • Stefansson K; deCODE Genetics/Amgen Inc., Reykjavik, Iceland; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Clin Microbiol Infect ; 28(6): 852-858, 2022 Jun.
Article em En | MEDLINE | ID: mdl-35182757
OBJECTIVES: The spread of SARS-CoV-2 is dependent on several factors, both biological and behavioural. The effectiveness of nonpharmaceutical interventions can be attributed largely to changes in human behaviour, but quantifying this effect remains challenging. Reconstructing the transmission tree of the third wave of SARS-CoV-2 infections in Iceland using contact tracing and viral sequence data from 2522 cases enables us to directly compare the infectiousness of distinct groups of persons. METHODS: The transmission tree enables us to model the effect that a given population prevalence of vaccination would have had on the third wave had one of three different vaccination strategies been implemented before that time. This allows us to compare the effectiveness of the strategies in terms of minimizing the number of cases, deaths, critical cases, and severe cases. RESULTS: We found that people diagnosed outside of quarantine (Rˆ=1.31) were 89% more infectious than those diagnosed while in quarantine (Rˆ=0.70) and that infectiousness decreased as a function of time spent in quarantine before diagnosis, with people diagnosed outside of quarantine being 144% more infectious than those diagnosed after ≥3 days in quarantine (Rˆ=0.54). People of working age, 16 to 66 years (Rˆ=1.08), were 46% more infectious than those outside of that age range (Rˆ=0.74). DISCUSSION: We found that vaccinating the population in order of ascending age or uniformly at random would have prevented more infections per vaccination than vaccinating in order of descending age, without significantly affecting the expected number of deaths, critical cases, or severe cases.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Humans / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Humans / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article